Evaluation of activity limitation in patients with idiopathic pulmonary fibrosis grouped according to Medical Research Council Dyspnea Grade

QR Code

Evaluation of activity limitation in patients with idiopathic pulmonary fibrosis grouped according to Medical Research Council Dyspnea Grade

Objective: To investigate the relations between Medical Research Council (MRC) dyspnea grade and peripheral muscle force, activities of daily living (ADL) performance, health status, lung function, and exercise capacity in subjects with idiopathic pulmonary fibrosis (IPF). Design: Prospective cross-...

Full description

Bibliographic Details
Main Authors:	Kozu, R., Jenkins, Susan, Senjyu, H.
Format:	Journal Article
Published:	W.B. Saunders Co. 2014
Subjects:	Rehabilitation Dyspnea Idiopathic pulmonary fibrosis
Online Access:	http://hdl.handle.net/20.500.11937/3469

Similar Items

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
by: Hutchinson, John P., et al.
Published: (2015)

The role of Interleukin-33 in the development of idiopathic pulmonary fibrosis
by: Stephenson, Katherine
Published: (2021)

Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century
by: Hutchinson, John P., et al.
Published: (2014)

Investigations into novel small molecules as potential treatments for idiopathic pulmonary fibrosis and malaria
by: Park, Jozef
Published: (2022)

Preparation of potent and selective αvβ6 integrin inhibitors for the treatment of idiopathic pulmonary fibrosis and synthetic approaches towards the total synthesis of mescengricin
by: Robinson, Henry Duncan
Published: (2021)

International comparative epidemiology of idiopathic pulmonary fibrosis
by: Hutchinson, John
Published: (2017)

The role of galectin-3 in the development of idiopathic pulmonary fibrosis
by: Parmar, Nimesh
Published: (2019)

Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF)
by: Barratt, Shaney L., et al.
Published: (2018)

cAMP mediated regulation of fibroblast to myofibroblast differentiation in idiopathic pulmonary fibrosis
by: Wright, Rebecca
Published: (2016)

Do the Trajectories of Dyspnea Differ in Prevalence and Intensity by Diagnosis at the End of Life? A Consecutive Cohort Study
by: Currow, D., et al.
Published: (2010)

Effect of disability level on response to pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis
by: Kozu, R., et al.
Published: (2011)

In vitro modelling of respiratory infections in idiopathic pulmonary fibrosis (IPF) using human induced pluripotent stem cell (hiPSCs)-derived alveolar epithelial type II cells
by: Serna Valverde, Ana Lilia
Published: (2023)

Refining in-vivo models of pulmonary fibrosis
by: Habgood, Anthony
Published: (2018)

Interplay between EZH2 and G9a regulates CXCL10 gene repression in idiopathic pulmonary fibrosis
by: Coward, William R., et al.
Published: (2017)

Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study
by: Jenkins, R. Gisli, et al.
Published: (2015)

Practical dyspnea assessment: relationship between the 0–10 numerical rating scale and the four-level categorical verbal descriptor scale of dyspnea intensity
by: Wysham, Nicholas G., et al.
Published: (2015)

Comorbidities and Medication Burden in Patients with Chronic Obstructive Pulmonary Disease Attending Pulmonary Rehabilitation
by: Noteboom, Ben, et al.
Published: (2014)

Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997-2008
by: Hutchinson, John P., et al.
Published: (2016)

Multimorbidity in patients with COPD and pulmonary rehabilitation
by: Hakamy, Ali
Published: (2018)

The potential therapeutic effect of manipulating the extracellular matrix in idiopathic pulmonary fibrosis
by: Philp, Christopher J.
Published: (2016)

Nebulized Furosemide for the Management of Dyspnea: Does the Evidence Support Its Use?
by: Newton, Phillip, et al.
Published: (2008)

Peak power estimated from 6-minute walk distance in Asian patients with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease
by: Kozu, R., et al.
Published: (2010)

Differences in Response to Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease
by: Kuzu, R., et al.
Published: (2011)

Socioeconomic deprivation and the outcome of pulmonary rehabilitation in England and Wales
by: Steiner, Michael C., et al.
Published: (2017)

Spatiotemporal regulation of anti-remodelling signalling pathways in primary human lung fibroblasts
by: Roberts, Maxine
Published: (2020)

The role of mesenchymal G proteins in pulmonary fibrosis and lung development
by: Goodwin, Amanda T.
Published: (2021)

Application of a human primary epithelial-fibroblast co-culture system to study fibrosis
by: Richardson, Jaineeta
Published: (2017)

Canine idiopathic chronic hepatitis
by: Bexfield, Nicholas
Published: (2017)

The inhibition of human lung fibroblast proliferation and differentiation by Gs-coupled receptors is not predicted by the magnitude of cAMP response
by: Roberts, Maxine J., et al.
Published: (2018)

The effect of pulmonary rehabilitation on mortality, balance, and risk of fall in stable patients with chronic obstructive pulmonary disease: a systematic review
by: Hakamy, Ali, et al.
Published: (2017)

Structure activity relationships of αv integrin antagonists for pulmonary fibrosis by variation in aryl substituents
by: Adams, James, et al.
Published: (2014)

An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation
by: Spruit, M., et al.
Published: (2013)

Quantification of the effects of operative management for idiopathic scoliosis: implications for pathogenesis, pathomechanisms and future management
by: Pratt, Roland K.
Published: (2002)

The use of the practice walk test in pulmonary rehabilitation program: National COPD Audit Pulmonary Rehabilitation Workstream
by: Hakamy, Ali, et al.
Published: (2017)

Suberoylanilide hydroxamic acid – a potential epigenetic therapeutic agent for lung fibrosis?
by: Wang, Z., et al.
Published: (2009)

Defining the mechanism of galectin-3-mediated TGF-β1 activation and its role in lung fibrosis
by: Calver, J.F.
Published: (2023)

Estimating endurance shuttle walk test speed using the six-minute walk test in people with chronic obstructive pulmonary disease
by: Wootton, S., et al.
Published: (2014)

The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: a randomised comparison
by: Prayle, A.P., et al.
Published: (2015)

Effect of epigenetic inhibitors on lung fibroblast phenotype change in idiopathic pulmonary fibrosis
by: Pasini, Alice, et al.
Published: (2016)

Effect of epigenetic inhibitors on lung fibroblast phenotype change in idiopathic pulmonary fibrosis
by: Pasini, Alice, et al.
Published: (2016)